CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01267253
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:21.672675+00:00
Published At: 2017-01-04T00:00:00+00:00
Record Updated At: 2019-03-20
Results Posted At: 2017-01-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Persistent Disease", "Recurrent Cervical Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-03-20"
protocolSection.identificationModule.nctId: "NCT01267253"
protocolSection.identificationModule.officialTitle: "A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-01-04"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.